Facial Erythema Treatment Market: Overview
Mostly, in the fair population facial erythema is seen. It is a condition where the face becomes red. The cause of this redness on the face is the dilation of the cutaneous blood vessels and the rise in the blood flow. In case of the dark skinned people, the facial erythema goes undiagnosed. Factors that cause the facial erythema, include the common skin diseases such as perioral dermatitis, rosacea, and systemic illness.
Facial Erythema Treatment Market: Facts
The US FDA has approved the Rhofade, Allergan (oxymetazoline hydrochloride 1% cream) for the cure of the persistent facial erythema which is generally associated with the rosacea. It is the first alpha1A adrenoceptor agonist that is approved by the FDA for the treatment of the persistent facial erythema.
Facial Erythema Treatment Market: Segmentation
The global market for the facial erythema treatment is fragmented into drug type, disease type, and distribution channel. On the basis of the drug type, the global market is segregated into antihistamines, antibiotics, calcineurin inhibitors, emollients, antifungal, and corticosteroids. On the basis of disease type, the market is categorized into papulopustular, ocular, erythematotelangiectatic, and phymatous. On the basis of the distribution channel, the market is divided into online pharmacies, hospital pharmacies, retail pharmacies, and others.
Facial Erythema Treatment Market: Growth Factors
The major factors that are contributing to the facial erythema treatment market are an increased rate of patient population, growing smoking population, increased consumption of the alcohol, changing climatic conditions, introduction to new products and the large pipeline of the drugs. Another factor that is contributing to the market growth is the technological developments that are made in this field. There are factors that are restraining the growth of the facial erythema treatment market which includes the growing generic competition and the regulations that are implemented on the approvals of the product.
Facial Erythema Treatment Market: Regional Analysis
The geographical diversification of the global facial erythema treatment market includes the Western European, Eastern Europe, Latin America, Middle East and Africa, and North America regions. The region that dominates the facial erythema treatment market is North America due to the factors such as the adoption of the treatments, the changing lifestyles of the people, and the increased number of fair population triggers the growth of the market in this region. The region that holds the second place is Europe and the factors that support this growth are the increasing consumption of the alcohol and the rise in the research and development activities. In the Asia Pacific region, the factors that support the growth of the market are changing lifestyle, increase in the growth of the population, the large influence of the Western lifestyle, a large pool of targeted patients, and the increase in the research and development activities.
Facial Erythema Treatment Market: Competitive Players
The key market players that are involved in the facial erythema treatment market include Astellas Pharma Inc., Meda Pharmaceuticals, Pfizer Inc., Sanofi S.A., Valeant Pharmaceuticals International, Inc., Anacor Pharmaceuticals Inc., Galderma S.A., Novartis International AG, and Regeneron Pharmaceuticals Inc.
Facial Erythema Treatment Market: Regional Segment Analysis
- North America
- U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- The Middle East and Africa
What Reports Provides
- Full in-depth analysis of the parent market
- Important changes in market dynamics
- Segmentation details of the market
- Former, on-going, and projected market analysis in terms of volume and value
- Assessment of niche industry developments
- Market share analysis
- Key strategies of major players
- Emerging segments and regional markets
- Testimonials to companies in order to fortify their foothold in the market.
